ZRSEF:OTC-Zur Rose Group AG (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 90

Change

0.00 (0.00)%

Market Cap

USD 1.12B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
ALBHF Alibaba Health Information Tec..

N/A

USD 7.22B
RADLY Raia Drogasil SA ADR

N/A

USD 6.95B
CLCGY Clicks Group Ltd

+0.52 (+1.39%)

USD 3.99B
SAEYY Shop Apotheke Europe N.V

+0.86 (+7.60%)

USD 2.48B
SHPPF Shop Apotheke Europe N.V

N/A

USD 2.28B
NVACF Nova Cannabis Inc

-0.03 (-2.85%)

USD 0.05B
NOTR Nowtransit Inc

N/A

USD 0.04B
RADCQ Rite Aid Corporation

+0.02 (+113.33%)

USD 0.01B
RXMD Progressive Care Inc

+0.12 (+7.62%)

USD 8.74M
HEWA Healthwarehouse.Com

N/A

USD 6.97M

ETFs Containing ZRSEF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.73% 73% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.73% 73% C 74% C
Trailing 12 Months  
Capital Gain 172.73% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 172.73% 100% F 95% A
Trailing 5 Years  
Capital Gain -0.12% 80% B- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.12% 80% B- 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 73.54% 68% D+ 81% B-
Dividend Return 73.54% 68% D+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 152.43% 40% F 26% F
Risk Adjusted Return 48.25% 96% N/A 85% B
Market Capitalization 1.12B 81% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector